Author(s): Piras S, Loriga M, Paglietti G
Abstract Share this page
Abstract Fourteen out of 21 quinoxaline derivatives described in the present paper were selected at NCI for evaluation of their in vitro anticancer activity. Preliminary screening showed that some derivatives exhibited a moderate to strong growth inhibition activity on various tumor panel cell lines between 10(-5) and 10(-4) M concentrations. Interesting selectivities were also recorded between 10(-8) and 10(-6) M for the compounds 9 and 13.
This article was published in Farmaco
and referenced in Biochemistry & Pharmacology: Open Access